Seçilmiş Yayınlar:

1)Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer. Feride Yılmaz, Serkan Yaşar, Ömer Denizhan Tatar, Hasan Çağrı Yıldırım, Deniz Can Güven, Arif Akyıldız, Elvin Chalabiyev, Burak Yasin Aktaş, Zafer Arık, Mustafa Erman. BMC Cancer. 2024 Oct 1;24(1):1218.

2)Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma.Hasan Cagri Yildirim, Ertuğrul Bayram, Elvin Chalabiyev, Nargız Majidova, Tugay Avci, Halil Göksel Güzel, Caner Kapar, Mehmet Uzun, Perihan Perkin, Fahri Akgül, Saadet Sim Yildirim, Seda Sali, Anil Yildiz, Seher Nazli Kazaz, Engin Hendem, Murat Arcagok, Gulnihal Tufan, Umit Yildirim, Omer Faruk Akgul, Çagatay Arslan, Hakan Taban, Eren Sahin, Melek Caglayan, Ramazan Esen, Berna Öksüzoğlu, Deniz Can Guven, Muhammet Ali Kaplan, Murat Araz, Mert Basaran, Erdem Cubukcu, Erhan Gokmen, Irfan Cicin, Efnan Algin, Huseyin Salih Semiz, Deniz Tural, Banu Ozturk, Atike Pinar Erdogan, Murat Sari, Oguz Kara, Mustafa Erman.J Chemother.2024 Sep 10:1-12.

3)Efficacy of Systemic Treatments in Patients With Metastatic Lung Invasive Mucinous Adenocarcinoma. Tarık Demir, Murat Araz, Carolyn Moloney, Engin Hendem, Mehmet Zahid Koçak, Mustafa Erman, Onur Baş, Osman Köstek, Nadiye Sever, Serdar Karakaya, Esra Zeynelgil, Liam Il-Young Chung, Young Kwang Chae. Clin Lung Cancer.2024 May 21:S1525-7304(24)00083-4.

4)Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with177Lu-PSMA-617. A single-center prospective observational study. Tugce Telli, Murat Tuncel, Erdem Karabulut, Sercan Aksoy, Mustafa Erman, Bulent Akdogan, Meltem Caglar. Prostate.2023 Jun;83(8):792-800.

5)The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors. Deniz Can Guven, Deniz Aral Ozbek 2, Taha Koray Sahin, Gozde Kavgaci, Melek Seren Aksun, Enes Erul, Hasan Cagri Yildirim, Elvin Chalabiyev, Cebrayil Cebroyilov, Tolga Yildirim, Omer Dizdar, Sercan Aksoy, Suayib Yalcin, Saadettin Kilickap, Mustafa Erman, Mustafa Arici. Anticancer Drugs.2023 Jul 1;34(6):783-790.

6)A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302). Primo N. Lara Jr, Luis Villanueva, Carolina Ibanez, Mustafa Erman, Jae Lyun Lee, Daniel Heinrich, Oleg Nikolaevich Lipatov, Craig Gedye, Erhan Gokmen, Alejandro Acevedo, Andrey Semenov, Se Hoon Park, Rustem Airatovich Gafanov, Fatih Kose, Mark Jones, Xiaoqi Du, Mihaela Munteanu, Rodolfo Perini, Toni K. Choueiri & Robert J. Motzer . Published: 25 July 2024, BMC Cancer, Volume 23, article number 1253, (2024)

7)NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. de Castro G Jr, Rizvi NA, Schmid P, Syrigos K, Martin C, Yamamoto N, Cheng Y, Moiseyenko V, Summers Y, Vynnychenko I, Lee SY, Bryl M, Zer A, Erman M, Timcheva C, Raja R, Naicker K, Scheuring U, Walker J, Mann H, Chand V, Mok T; NEPTUNE Investigators. J Thorac Oncol. 2023 Jan;18(1):106-119. doi: 10.1016/j.jtho.2022.09.223. Epub 2022 Oct 12.

8)Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Levy B, Barlesi F, Paz-Ares L, Bennouna J, Erman M, Felip E, Isla D, Ryun Kim H, Kim SW, Madelaine J, Molinier O, Özgüroğlu M, Rodríguez Abreu D, Adeniji A, Lorence RM, Voccia I, Chisamore MJ, Riess JW. Lung Cancer. 2022 Apr;166:107-113. doi: 10.1016/j.lungcan.2022.01.023. Epub 2022 Feb 3.

9)Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, Majem M, Nackaerts K, Syrigos K, Hansen K, Schuette W, Cetnar J, Cappuzzo F, Okamoto I, Erman M, Langer SW, Kato T, Groen H, Sun Z, Luo Y, Tanwani P, Caffrey L, Komarnitsky P, Reinmuth N. J Thorac Oncol. 2021 Sep;16(9):1547-1558. doi: 10.1016/j.jtho.2021.02.009. Epub 2021 Feb 16.

Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study. Erman M, Biswas B, Danchaivijitr P, Chen L, Wong YF, Hashem T, Lim CS, Karabulut B, Chung HJ, Chikatapu C, Ingles S, Slimane K, Kanesvaran R. BMC Cancer. 2021 Sep 14;21(1):1021. doi: 10.1186/s12885-021-08738

• Akciğer kanseri ve diğer torasik kanserler (mezotelyoma, timik karsinom vb.) • Genitoüriner kanserler: Böbrek, prostat, mesane ve testis tümörleri • Klinik araştırmalar, Faz I çalışmalar • Kemoterapi, immünoterapi ve diğer hedefe yönelik tedaviler

: (312) 305 43 30

: ermanm@hacettepe.edu.tr